BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 8883278)

  • 1. A prothrombinase-based assay for detection of resistance to activated protein C.
    Nicolaes GA; Thomassen MC; van Oerle R; Hamulyak K; Hemker HC; Tans G; Rosing J
    Thromb Haemost; 1996 Sep; 76(3):404-10. PubMed ID: 8883278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteolysis of factor V by cathepsin G and elastase indicates that cleavage at Arg1545 optimizes cofactor function by facilitating factor Xa binding.
    Camire RM; Kalafatis M; Tracy PB
    Biochemistry; 1998 Aug; 37(34):11896-906. PubMed ID: 9718313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of (pre-)analytical variables on activated protein C resistance determined via a thrombin generation-based assay.
    Curvers J; Christella M; Thomassen LG; de Ronde H; Bertina RM; Rosendaal FR; Tans G; Rosing J
    Thromb Haemost; 2002 Mar; 87(3):483-92. PubMed ID: 11924538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factor V enhances the cofactor function of protein S in the APC-mediated inactivation of factor VIII: influence of the factor VR506Q mutation.
    Váradi K; Rosing J; Tans G; Pabinger I; Keil B; Schwarz HP
    Thromb Haemost; 1996 Aug; 76(2):208-14. PubMed ID: 8865533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance to activated protein C due to mutated factor V as a novel cause of inherited thrombophilia.
    De Stefano V; Leone G
    Haematologica; 1995; 80(4):344-56. PubMed ID: 7590506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical evaluation of a functional prothrombin time-based assay for identification of factor V Leiden carriers in a group of Italian patients with venous thrombosis.
    Gessoni G; Valverde S
    Blood Coagul Fibrinolysis; 2007 Oct; 18(7):603-10. PubMed ID: 17890946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of activated protein C on thrombin generation and on the thrombin potential in plasma of normal and APC-resistant individuals.
    Nicolaes GA; Thomassen MC; Tans G; Rosing J; Hemker HC
    Blood Coagul Fibrinolysis; 1997 Jan; 8(1):28-38. PubMed ID: 9105635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. "Pseudo homozygous" activated protein C resistance due to double heterozygous factor V defects (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: report of two cases belonging to two unrelated kindreds.
    Simioni P; Scudeller A; Radossi P; Gavasso S; Girolami B; Tormene D; Girolami A
    Thromb Haemost; 1996 Mar; 75(3):422-6. PubMed ID: 8701401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phospholipid-bound tissue factor modulates both thrombin generation and APC-mediated factor Va inactivation.
    Váradi K; Siekmann J; Turecek PL; Schwarz HP; Marder VJ
    Thromb Haemost; 1999 Dec; 82(6):1673-9. PubMed ID: 10613654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Laboratory diagnosis of hereditary thrombophilia.
    Michiels JJ; Hamulyák K
    Semin Thromb Hemost; 1998; 24(4):309-20. PubMed ID: 9763348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human factor Va1 and factor Va2: properties in the procoagulant and anticoagulant pathways.
    Hoekema L; Nicolaes GA; Hemker HC; Tans G; Rosing J
    Biochemistry; 1997 Mar; 36(11):3331-5. PubMed ID: 9116011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coagulation factor V: an old star shines again.
    Rosing J; Tans G
    Thromb Haemost; 1997 Jul; 78(1):427-33. PubMed ID: 9198191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter evaluation of a kit for activated protein C resistance on various coagulation instruments using plasmas from healthy individuals. The APC Resistance Study Group.
    Rosén S; Johansson K; Lindberg K; Dahlbäck B
    Thromb Haemost; 1994 Aug; 72(2):255-60. PubMed ID: 7831662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of prothrombinase activity by protein S.
    van 't Veer C; Butenas S; Golden NJ; Mann KG
    Thromb Haemost; 1999 Jul; 82(1):80-7. PubMed ID: 10456458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved distinction of factor V wild-type and factor V Leiden using a novel prothrombin-based activated protein C resistance assay.
    Wilmer M; Stocker C; Bühler B; Conell B; Calatzis A
    Am J Clin Pathol; 2004 Dec; 122(6):836-42. PubMed ID: 15539375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional activated protein C resistance assays: correlation with factor V DNA analysis is better with RVVT-than APTT-based assays.
    Favaloro EJ; Mirochnik O; McDonald D
    Br J Biomed Sci; 1999; 56(1):23-33. PubMed ID: 10492912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteolytic events that regulate factor V activity in whole plasma from normal and activated protein C (APC)-resistant individuals during clotting: an insight into the APC-resistance assay.
    Kalafatis M; Haley PE; Lu D; Bertina RM; Long GL; Mann KG
    Blood; 1996 Jun; 87(11):4695-707. PubMed ID: 8639839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiolipin enhances protein C pathway anticoagulant activity.
    Fernández JA; Kojima K; Petäjä J; Hackeng TM; Griffin JH
    Blood Cells Mol Dis; 2000 Apr; 26(2):115-23. PubMed ID: 10753602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma factor V activation is prevented by activated protein C in the presence of phospholipid vesicles, not platelets.
    Solymoss S; Nguyen KT
    Thromb Haemost; 1993 Feb; 69(2):124-9. PubMed ID: 8456424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. beta 2-Glycoprotein I modulates the anticoagulant activity of activated protein C on the phospholipid surface.
    Mori T; Takeya H; Nishioka J; Gabazza EC; Suzuki K
    Thromb Haemost; 1996 Jan; 75(1):49-55. PubMed ID: 8713779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.